SearchDictionaryMobileLogin

Sandeep Tyagi Selected Research

Tuberculosis

10/2008Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
04/2008Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
12/2007Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
12/2007In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
08/2006Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
07/2006Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
12/2005Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
12/2005Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
06/2005Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
11/2004Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
02/2004Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
06/2002Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

Articles by Research Topic

Disease

12Tuberculosis
10/2008 - 06/2002

Drug/Important Bio-Agent (IBA)

7moxifloxacin (Avelox)FDA Link
04/2008 - 06/2002
4PA 824IBA
10/2008 - 06/2005
4rifapentine (Priftin)FDA Link
12/2007 - 12/2005
2PyrazinamideFDA LinkGeneric
10/2008 - 04/2008
1Rifampin (Rifampicin)FDA LinkGeneric
10/2008
1DNA (Deoxyribonucleic Acid)IBA
12/2005

Therapy/Procedure

1Combination Drug Therapy (Combination Chemotherapy)
08/2006